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Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
degeneration with ubiquitin positive inclusions (FTLD-U) are
two clinically distinct neurodegenerative conditions sharing a
similar histopathology characterized by the nuclear clearance of
TDP-43 and its associated deposition into cytoplasmic inclu-
sions in different areas of the central nervous system. Given the
concomitant occurrence of TDP-43 nuclear depletion and cyto-
plasmic accumulation, it has been proposed that TDP-43 pro-
teinopathies originate from either a loss-of-function (LOF)
mechanism, a gain-of-function (GOF) process, or both.Wehave
addressed this issue by transfecting murine NSC34 and N2a
cells with siRNA for endogenous murine TDP-43 and with
human recombinant TDP-43 inclusion bodies (IBs). These two
strategies allowed the depletion of nuclear TDP-43 and the
accumulation of cytoplasmic TDP-43 aggregates to occur sepa-
rately and independently. Endogenous and exogenous TDP-43
weremonitored andquantifiedusingboth immunofluorescence
and Western blotting analysis, and nuclear functional TDP-43
was measured by monitoring the sortilin 1 mRNA splicing
activity. Various degrees of TDP-43 cytoplasmic accumulation
and nuclear TDP-43 depletion were achieved and the resulting
cellular viability was evaluated, leading to a quantitative global
analysis on the relative effects of LOF and GOF on the overall
cytotoxicity. These were found to be 55% and 45%, respec-
tively, in both cell lines and using both readouts of cell toxicity,
showing that these two mechanisms are likely to contribute
apparently equally to the pathologies of ALS and FTLD-U.
Amyotrophic lateral sclerosis (ALS)2 and frontotemporal
lobar degeneration with ubiquitin positive inclusions
(FTLD-U) are neurodegenerative conditions with distinct clin-
ical profiles but sharing a similar histopathology characterized
by the cytoplasmic deposition of proteinaceous inclusions of
the TAR DNA-binding protein 43 (TDP-43) in different
regions of the central nervous system (1, 2).
From a clinical viewpoint, ALS is characterized by progres-
sive muscle weakness, atrophy, fasciculation, spasticity, diffi-
culty in moving, speaking, swallowing, and breathing, with
all these symptoms reflecting progressive degeneration of
motoneurons of the primarymotor cortex, corticospinal tracts,
brainstem, and spinal cord (3, 4). TDP-43 inclusion formation
involves the cytosol of upper and lower motoneurons of the
brain, brainstem, and spinal cord in all patients, and of neurons
of the frontotemporal cortex and hippocampus in a subset of
cases (1, 2). Inclusion bodies of TDP-43 were also found in the
glial cells of the brainstem and spinal cord of ALS patients (2).
FTLD is a form of cortical dementia involving degeneration
of the frontal and temporal lobes of the brain (5). It is charac-
terized either by changes in personality and behavior or by lan-
guage dysfunction (aphasia). In neuropathological terms, FTLD
can be divided in three forms: FTLD with tau-positive inclu-
sions, FTLD with tau-negative, ubiquitin-positive, and TDP-
43-positive inclusions (FTLD-U or FTLD-TDP), and FTLD
with ubiquitin-positive inclusions that are also positive for the
fused in sarcoma protein (FTLD-FUS). In FTLD-TDP the
inclusions aremainly cytoplasmic and are present in the frontal
and temporal cortices, hippocampus, with the frequent
involvement of brainstem and spinal cord motor neurons (1).
In both ALS and FTLD-U the formation of cytoplasmic
TDP-43 inclusions in neurons and motoneurons is accompa-
nied by post-translational modifications of the TDP-43 protein
(1). Thesemodifications includeN-terminal truncation, to gen-
erate a mixture of full-length protein and C-terminal frag-
ments, hyperphosphorylation and ubiquitination. In addition,
the accumulation of TDP-43 in the cytoplasm occurs concom-
itantly with its depletion from the nucleus, where TDP-43 nor-
mally resides in its soluble and functional form. Given the
concomitant occurrence of TDP-43 nuclear depletion and
cytoplasmic accumulation, it has been proposed that TDP-43
proteinopathies originate either from a loss-of-function (LOF)
mechanism, resulting from a decrease of functional TDP-43
levels in the nucleus, a gain-of-function (GOF) mechanism,
resulting from the formation of potentially harmful TDP-43
cytoplasmic inclusions, or a combination of the two mecha-
nisms (6–11). If both mechanisms are at work, as many inves-
tigators suppose, it has not yet been established which of the
two is themost prominent contributor to the disease pathology.
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Studies in mammalian cell cultures and animal models have
not clarified this issue. In cultured mammalian cells, for exam-
ple, overexpression of full-length TDP-43 generally results in a
nuclear enrichment of TDP-43 in the absence of cytosolic mis-
localization (12–20), and in no, or only low, levels of cellular
damage (15, 17–20). Expression of C-terminal fragments of the
protein (Ct TDP-43) or of protein lacking the nuclear localiza-
tion signal (NLS TDP-43), has resulted in cytoplasmic inclu-
sion formation and nuclear depletion, with the cytoplasmic
inclusions found to recruit nuclear TDP-43 (12–16, 20). Trans-
location of TDP-43 from the nucleus to the cytoplasm has been
found to result in marked toxicity (15, 20), but it has been dif-
ficult to induce nuclear clearance and inclusion formation sep-
arately. Importantly, knockdown experiments of TDP-43 in
Neuro2a cells were found to inhibit neurite growth, diminish
cell viability, and induce apoptosis, indicating that loss of func-
tional nuclear TDP-43 is intrinsically deleterious (13, 21).
Overexpression of full-length TDP-43 in transgenicmice has
resulted in neuronal loss and phenotypic abnormalities in part
reminiscent of ALS and FTLD in a clear dose-dependent man-
ner (22–28). In these animals, TDP-43 overexpression has often
led to enrichment of TDP-43 in the nucleus in the absence of
significant formation of cytoplasmic inclusions, thereby indi-
cating that an increase in nuclear TDP-43 levels is sufficient to
trigger neurodegeneration (22–28). In a few cases where inclu-
sions form in combinationwith nuclear depletion, however, the
phenotypic abnormalities have appeared to bemore severe (23,
24, 26, 28, 29), suggesting that both events could contribute to
cellular damage. As in the cell culture experiments, however, it
has been difficult to induce nuclear clearance and cytosolic
accumulation separately and hence to evaluate their individual
contributions to the observed toxicity. Importantly, complete
loss of TDP-43 inmurine knock-out experiments have resulted
in early embryonic lethality, implying that the presence of func-
tional nuclear TDP-43 is essential for life (30–32).
In the light of all these studies, it is clear that the major prob-
lem in establishing a fundamental distinction between LOF and
GOF mechanisms in ALS and FTLD-U originates from the
simultaneous occurrence of nuclear depletion and cytoplasmic
accumulation of TDP-43 in human patients, as well as in their
related animal and cell culturemodels. In addition, overexpres-
sion of TDP-43 in cell cultures or transgenic animals often
results in enrichment of TDP-43 in the nucleus and toxicity, in
the absence of any significant mislocalization of the protein,
complicating still further the elucidation of this issue. In this
paper we have utilized a combined approach to dissect TDP-43
nuclear depletion and cytosolic accumulation of TDP-43 in
cells. We have first transiently overexpressed human TDP-43
to different degrees and reproduced previous findings of
nuclear enrichment at normally used levels of expression and
nucleus-to-cytosol mislocalization at very high expression lev-
els.We have then used RNA interference and internalization of
preformed inclusion bodies containingTDP-43, with the aimof
causing nuclear depletion of TDP-43 in the absence of mislo-
calization, and accumulation of cytosolic TDP-43 aggregates in
the absence of nuclear alterations, respectively. This approach
has allowed us to evaluate the GOF and LOF contributions to
cytotoxicity separately and to quantify their relative roles in the
overall toxicity caused by the aberrant behavior of TDP-43.
Results
Overexpression of Human TDP-43 in NSC34 Cells Caused
Both Nuclear Depletion and Cytoplasmic Accumulation—We
first transfected murine NSC34 cells transiently with different
quantities (1–20g) of the pCI-neo plasmid expressing human
TDP-43. The presence of TDP-43 in the cells was assessed 48 h
later, using confocal microscopy and monoclonal anti-TDP-43
antibodies that recognize both endogenous (murine) and exog-
enous (human) TDP-43. Cells transfected with vehicle showed
the expected nuclear localization of TDP-43 (Fig. 1). Cells
transfected with moderate quantities of plasmid (1–4 g)
FIGURE 1. A, representative confocal scanning microscope images of murine
NSC34 cells transiently transfectedwith different quantities (0–20g) of pCI-
neo plasmid expressing human TDP-43 and acquired after 48 h. The green
fluorescence indicates TDP-43 detected with antibodies that recognize both
the endogenous (murine) and exogenous (human) protein. B, semi-quantita-
tive analysis of nuclear (green), cytoplasmic (pale green) and total (dark green)
TDP-43-derived fluorescence, represented as a percentage relative to the
nuclear fluorescence detected after transfection with vehicle. Experimental
errors are S.E. The single (*), double (**), and triple (***) asterisks refer to p
values lower than 0.05, 0.01, and 0.001, respectively, relative to nuclear or
cytoplasmic TDP-43-derived fluorescence of cells transfected with vehicle.
LOF and GOFMechanisms of TDP-43 Proteinopathies
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showed a significant increase in nuclear TDP-43 levels, where-
as the cytoplasmic TDP-43-derived fluorescence remained
almost unchanged (Fig. 1). By contrast, cells transfected with
higher amounts of plasmid (6–10 g) showed a progressive
accumulation of the overexpressed protein in the cytosol along
with progressive nuclear clearance (Fig. 1). In particular, trans-
fection of the cells with 10 g of plasmid led to a significant
decrease in nuclear TDP-43 and a large increase in cytoplasmic
TDP-43, mimicking the redistribution of TDP-43 from the
nucleus to the cytoplasm observed in pathological situations.
Moreover, TDP-43 accumulating in the cytosol appeared to be
ubiquitinated and phosphorylated at Ser-409/410, as shown by
immunofluorescence using antibodies against TDP-43, ubiqui-
tin and phosphorylated TDP-43, again in agreement with the
post-translationalmodifications of TDP-43 observed in pathol-
ogy (supplemental Fig. S1). Transfection with yet larger
amounts of plasmid (15–20g) resulted in a progressive reduc-
tion of both nuclear and cytoplasmic TDP-43, probably as a
consequence of an autoregulation process of the protein (33)
and clearance processes mediated by the cells (Fig. 1).
A time-course analysis showed that cells transfected with 4
g of plasmid underwent a progressive increase in nuclear
TDP-43-derived fluorescence at times up to 48 h after transfec-
tion, with a significant reduction after 72 h (Fig. 2, A and B),
probably a result of the transient nature of our transfection. By
contrast, cytoplasmic TDP-43 levels were not significantly
modified (Fig. 2, A and B). Cells transfected with 10 g of plas-
mid showed a significant increase in nuclear TDP-43-derived
fluorescence only 24 h after transfection, followed by a signifi-
cant decrease after 48 h and a dramatic decrease after 72 h (Fig.
2, A and B). This pattern is likely to be due to the progressive
accumulation of TDP-43 in the cytoplasm, which reached a
maximum value 48 h after transfection and was able to recruit
nuclearTDP-43 (Fig. 2,A andB). These eventswere followedby
a significant decrease of both nuclear and cytoplasmic TDP-43
levels 72 h after transfection (Fig. 2, A and B), again probably
due to the transient nature of our transfection.
We also monitored the levels of endogenous TDP-43 in the
same experiments, using polyclonal antibodies that specifically
recognizemurine TDP-43. The cross-reactivity of the anti-mu-
FIGURE 2. A and C, representative confocal scanningmicroscope images of murine NSC34 cells transiently transfected with 0, 4, and 10g of pCI-neo plasmid
expressing human TDP-43, analyzed 0, 24, 48, and 72 h after transfection. The green and red fluorescence indicates TDP-43 detected with antibodies that
recognize both endogenous and exogenous protein (A) and only endogenous protein (C), respectively. B and D, semi-quantitative analyses of nuclear (filled
symbols) and cytoplasmic (empty symbols) TDP-43-derived fluorescence upon transfectionwith 0 (triangles), 4 (squares), and 10 (circles)g of plasmid. The two
plots refer to antibodies that recognize both the endogenous and exogenous protein (B) and only the endogenous protein (D), respectively. Experimental
errors are S.E. The single (*), double (**), and triple (***) asterisks refer top values lower than0.05, 0.01, and0.001, respectively, relative tonuclear or cytoplasmic
TDP-43 derived fluorescence of cells transfected with vehicle.
LOF and GOFMechanisms of TDP-43 Proteinopathies
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rine TDP-43 antibodies with human TDP-43 was excluded
(supplemental Fig. S2). Cells transfected with 4 g of plasmid
showed that endogenous TDP-43 remained unmodified and
that translocation of endogenous TDP-43 to the cytoplasm
had not taken place (Fig. 2, C and D). This result indicates that
the levels of nuclear endogenous TDP-43 did not change with
time following overexpression of exogenous TDP-43, and that
the time-dependent change of the total TDP-43 observed in the
nucleus can be attributed to the transient overexpression of
exogenous TDP-43. In contrast, cells transfected with 10 g of
plasmid showed a time-dependent translocation of endoge-
nous TDP-43 from the nucleus to the cytoplasm (Fig. 2, C and
D). This result indicates that there is sequestration of endoge-
nous nuclear TDP-43 by the cytoplasmic exogenous protein,
which also accumulates in the cytoplasm under these condi-
tions of transfection.
We next assessed the viability of the NSC34 cells expressing
exogenous TDP-43 for 48 h bymeasuring their ability to reduce
MTT (Fig. 3A) and to activate caspase-3 (Fig. 3,B andC). These
experiments showed that TDP-43 overexpression generated
toxicity, the degree of which increased with the quantities of
transfected plasmid. Toxicity was significant following trans-
fection with 4 g of plasmid for 48 h, i.e. under conditions that
were accompanied by nuclear TDP-43 accumulation but with-
out significant cytoplasmic accumulation, indicating that an
increase in the levels of nuclear TDP-43 is deleterious to the
cells (Fig. 3). The toxicity was significantly higher with 10 g of
plasmid, where both nuclear depletion and cytoplasmic accu-
mulation of TDP-43were evident, indicating that the combina-
tion of these events is very highly deleterious to the cells (Fig. 3).
Such toxicity could result either from a gain-of-function (GOF)
of the accumulated cytoplasmic protein, a loss-of-function
(LOF) of the nuclear protein, or both.
Loss of Functional TDP-43 by siRNA Results in Significant
Toxicity in NSC34 Cells—To cause nuclear depletion and cyto-
solic accumulation of TDP-43 separately and independently of
each other, and assess their corresponding effects on the cells,
we used two strategies: knockdown of endogenous TDP-43 and
cell transfection with pre-formed TDP-43 aggregates. We
achieved knockdown of endogenous TDP-43 in NSC34 cells by
using siRNA, as described in “Experimental Procedures.” Con-
focal microscopy images of cells transfected with vehicle or
control siRNA, the latter consisting of a pool of 4 non-targeting
siRNAs, did not show any changes in the levels of nuclear or
cytosolic TDP-43-derived fluorescence over a period of 72 h
(Fig. 4, A and B). By contrast, cells transfected with siRNA spe-
cific for TDP-43 showed a highly significant time-dependent
reduction of nuclear TDP-43-derived fluorescence, in the
absence of any detectable cytosolic fluorescence (Fig. 4, A and
B). Since we achieved different levels of TDP-43 mRNA silenc-
ing by varying the time of incubation after siRNA transfection,
for this and following analyses we varied this parameter, while
maintaining unaltered the quantity of siRNA used in our
transfection.
We also assessed the functionality of nuclear TDP-43 by
monitoring its regulation of the splicing activity of the mRNA
transcribed from the mouse sortilin 1 (Sort1) gene, as previ-
ously described (34). Cells transfected with vehicle and control
siRNA showed, after 72 h, an intense band at 250 bp and a weak
band at 350 bp, indicating inhibition of the inclusion of the
sortilin exon cassette (termed Ex17b) in the Sort1 mRNA and
FIGURE 3. A, MTT reduction of NSC34 cells 48 h following transfection with
different quantities (0–20g) of pCI-neo plasmid expressing human TDP-43.
B, representative confocal microscope images showing caspase-3 activation
in NSC34 cells, assessed using the fluorescent probe FAM-FLICA™ caspases 3
and 7. The images were acquired 48 h following transfection with different
quantities (0–20 g) of pCI-neo plasmid expressing human TDP-43. C, semi-
quantitative analysis of the green fluorescence arising from caspase-3 activa-
tion. Experimental errors are S.E. The single (*), double (**), and triple (***)
asterisks refer to p values lower than 0.05, 0.01, and 0.001, respectively, rela-
tive to cells transfected with vehicle.
LOF and GOFMechanisms of TDP-43 Proteinopathies
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the presence of a functional TDP-43 (Fig. 4C). By contrast, cells
transfected with siRNA specific for TDP-43 showed, after 72 h,
a weaker band at 250 bp and a more intense band at 350 bp,
significantly different from those observed with vehicle or con-
trol siRNA, as assessed by densitometric analysis of RT-PCR
(Fig. 4C). This result indicates that the Ex17b exon cassette had
been largely included in themRNA and the function of TDP-43
as a regulator of the Sort1 mRNA splicing was partially
impaired (Fig. 4C).
Transfection with control siRNA was found to be innocuous
to the cells, whereas transfection with TDP-43-specific siRNA
induced significant toxicity, which increased with time, as
detected with the MTT reduction assay and the measurement
of caspase-3 activation (Fig. 4,D–F). These data suggest that the
loss of nuclear, functional TDP-43 is intrinsically toxic and
plays an important role in the cytotoxicity associated with
TDP-43 pathology, independently of the accumulation of cyto-
plasmic TDP-43.
FIGURE 4. A, representative confocal scanningmicroscope images of NSC34 cells transfected with vehicle, 25 nM siRNA and 25 nM control siRNA and analyzed
0, 48, 63, and72hafter transfection. Thegreen fluorescence indicates TDP-43detectedwith immunofluorescence.B, semi-quantitative analysis of nuclear (filled
symbols) and cytoplasmic (empty symbols) TDP-43-derived fluorescence upon transfection with vehicle (triangles), siRNA (squares), and control siRNA (circles).
C, splicing analysis of the mouse sortilin 1 (Sort1) gene upon TDP-43 silencing and corresponding densitometric analysis in NSC34 cells. The inclusion of the
sortilin exon cassette (Ex17b) is generated upon TDP-43 down-regulation resulting in a 350-bp band. NSC34 cells were transfected with vehicle, 25 nM control
siRNA, and 25 nM siRNA and analyzed after 72 h. D, MTT reduction of NSC34 cells transfected with siRNA and analyzed 0, 48, 63, and 72 h after transfection. E,
representative confocalmicroscope images showing caspase-3 activation in NSC34 cells, assessed using the fluorescent probe FAM-FLICA™ caspases 3 and 7.
The images were acquired at the indicated times, following transfection with vehicle or 25 nM siRNA. F, semi-quantitative analysis of the green fluorescence
arising from caspase-3 activation. Experimental errors are S.E. The double (**) and triple (***) asterisks refer to p values lower than 0.01 and 0.001, respectively,
relative to cells transfected with vehicle.
LOF and GOFMechanisms of TDP-43 Proteinopathies
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Internalization of TDP-43 IBs Generated a Significant Toxic-
ity in NSC34 Cells—To assess the contribution of cytoplasmic
TDP-43 inclusions on cellular toxicity, we used bacterial inclu-
sion bodies (IBs) purified from Escherichia coli cells after over-
expression of human TDP-43 (TDP-43 IBs), as well as IBs puri-
fied from E. coli cells after overexpression of the same plasmid
devoid of the TDP-43 gene (control IBs). We first assessed the
content of the TDP-43 IBs formed in E. coli, and TDP-43 was
detected only in the pellet (P) fraction after cell lysis, indicating
that it had aggregated and become located in the IBs after over-
expression (supplemental Fig. S3, A and B). Following purifica-
tion of the IBs from E. coli cell lysates, TDP-43 was again
detected only in the P fraction, indicating that it had main-
tained its aggregated state until the end of the IB purification
procedure (supplemental Fig. S3, A and B). This analysis also
showed that TDP-43 IBs contained 30% TDP-43 and 70% of
other proteins (supplemental Fig. S3B); we therefore used con-
centrations of TDP-43 IBs that were 30% higher than control
IBs so that the two sets of IBs contained the same quantities of
non-TDP-43 proteins and differed only in the presence, in the
first case, of TDP-43 aggregates. Using this approach, it was
possible to evaluate the effects of TDP-43 aggregates within the
IBs relative to other aggregated proteins present in IBs by ana-
lyzing the differences between control IBs and TDP-43 IBs.
To allow the cellular internalization of purified TDP-43 IBs
and control IBs into NSC34 cells we used reagents containing
cationic amphiphilic molecules. NSC34 cells transfected with
vehicle or 16 g/ml of control IBs showed the presence of
endogenous nuclear TDP-43, in the absence of any accumula-
tion in the cytoplasm (Fig. 5, A and B). In contrast, cells trans-
fected with TDP-43 IBs showed cytoplasmic TDP-43 accumu-
lation, which increased with the IB concentration, without any
significant modification of endogenous nuclear TDP-43 (Fig. 5,
A and B). Antibodies specific for murine TDP-43 confirmed
that the newly accumulated cytoplasmic TDP-43 was entirely
exogenous (human) and that the levels of endogenous nuclear
TDP-43 (murine) were unchanged following TDP-43 IB trans-
fection (Fig. 5C). We also examined the splicing of the Sort1
mRNA; cells transfected with vehicle, 4 g/ml of control IBs
and 5.7g/ml of TDP-43 IBs, all showed an intense band at 250
bp and a weak band at 350 bp, indicating that the Ex17b
sequence had not been included in the Sort1 mRNA and there-
fore that the endogenous nuclear TDP-43 maintained its func-
tion as a regulator of the Sort1mRNA splicing after IB internal-
ization (Fig. 5D).
To assess the aggregation state of the exogenous TDP-43,
newly inserted in the cytosol of NSC34 cells using TDP-43 IBs,
we purified the cytoplasmic fraction of the cells transfected
with 5.7 g/ml of TDP-43 IBs, separated the soluble and
insoluble fractions by centrifugation and analyzed the result-
ing supernatant (SN) and pellet (P) fractions using West-
ern blotting and anti-TDP-43 antibodies. The exogenous
TDP-43 was detected only in the P fraction, indicating that it
maintained its aggregated state after cellular internalization
(supplemental Fig. S3C). Moreover, the newly inserted, cytoso-
lic TDP-43 protein appeared to be ubiquitinated and, at least in
part, phosphorylated, as shown by immunofluorescence, mim-
icking the post-translational modifications observed in patho-
logical situations (supplemental Fig. S4, A and B). The phos-
phorylation of TDP-43 IBs was also assessed by Western
blotting and anti-TDP-43 phosphorylation sites 409/410
antibodies (supplemental Fig. S4C).
We next analyzed the viability of NSC34 cells treated with
1.425–22.8g/ml ofTDP-43 IBs andwith 16.0g/ml of control
IBs, the latter corresponding to the highest concentration of
TDP-43 IBs (30% lower). Cells treated with control IBs showed
a low level of cytotoxicity, attributable to the aggregated protein
present in the IBs (Fig. 5, E–G). Cells treated with TDP-43 IBs
showed a much higher cytotoxicity, which increased with IB
concentration (Fig. 5, E–G). Since 16 g/ml of control IBs and
22.8 TDP-43 IBs differed only in the presence of TDP-43, the
higher toxicity observed with both assays for TDP-43 IBs rela-
tive to control IBs can be attributed to the aggregated TDP-43
present in the IBs. These results suggest that the accumulation
ofTDP-43 aggregates in the cytoplasm intrinsically induces cel-
lular toxicity and is therefore likely to play an important role in
the cytotoxicity associated with TDP-43 pathology, indepen-
dently of TDP-43 nuclear depletion.
Quantification of GOF and LOF Contributions to Toxicity in
NSC34 Cells—To assess further the correlation between
nuclear levels of TDP-43 and cytotoxicity we took into account
the conditions of both TDP-43 overexpression with the pCI-
neo plasmid and TDP-43 silencing with siRNA, in which
nuclear TDP-43 levels changed without any significant modifi-
cation of those in the cytoplasm. To this aim, we analyzed the
MTT results of NSC34 cells transfected with moderate
amounts of plasmid (1, 2, 4 g) and with siRNA at different
times (48, 63, 72 h). The resulting correlation between MTT
reduction and nuclear TDP-43 derived fluorescence was found
to fit well to a second order polynomial function, i.e. to a para-
bolic function (Fig. 6A). Both increases and decreases of nuclear
TDP-43 levels, relative to physiological levels, were found to
cause a reduction of cell viability (Fig. 6A). We repeated the
analysis using measurements of caspase-3 activation as a probe
of NSC34 cell toxicity and obtained a clearly similar correlation
(Fig. 6B).
To assess the relationship between cytoplasmic levels of
TDP-43 and cytotoxicity we considered both the conditions of
TDP-43 overexpression and TDP-43 IB internalization in
which cytoplasmic TDP-43 levels changed without any signifi-
cant decrease of those in the nucleus. To this end, we consid-
ered the MTT results of NSC34 cells transfected with 8 g of
plasmid and with control IBs and TDP-43 IBs (1.425–22.8
g/ml). A plot of MTT reduction versus cytoplasmic TDP-43
derived fluorescence revealed that an increase in cytoplasmic
TDP-43 levels correlates strongly with a reduction of cell via-
bility (Fig. 6C). The resulting correlation was not only highly
significant, but appeared to be approximately linear (Fig. 6C).
We obtained an even more significant correlation using mea-
surements of caspase-3 activation as a probe of NSC34 cell tox-
icity (Fig. 6D).
Using the equations of best fit for the two correlations of Fig.
6, A and B, we determined the decrease in MTT reduction and
the increase in caspase-3 activation for a 50% loss of nuclear
TDP-43 relative to the nuclear TDP-43 estimated after trans-
fectionwith vehicle. Similarly, using the equations of best fit for
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the two correlations of Fig. 6, C and D, we determined the
decrease in MTT reduction and the increase in caspase-3 acti-
vation for a 50% accumulation of cytoplasmic TDP-43 relative
to the nuclear TDP-43 estimated after transfection with vehi-
cle. This calculation was carried out by interpolating the values
of MTT reduction and caspase-3 activation on the y axis corre-
sponding to a nuclear TDP-43-derived fluorescence of 50% on
the x axis (Fig. 6, A and B) or to a cytoplasmic TDP-43-derived
fluorescence of 50% on the x axis (Fig. 6, C and D). The values
obtained at 50% of vehicle nuclear TDP-43 allow to compare
similar levels of toxicity when the same levels of TDP-43 are
depleted form the nucleus (Fig. 6, A and B) or present in the
cytoplasm (Fig. 6, C and D). To allow the comparison between
different parameters of toxicity, the values of caspase-3 activa-
FIGURE 5.A, representative confocal scanningmicroscope images ofNSC34 cells transfectedwith vehicle, 16g/ml of control IBs, anddifferent concentrations
of TDP-43 IBs and analyzed after transfection. The green fluorescence indicates total TDP-43 (human and murine) detected with immunofluorescence. B,
semi-quantitative analysis of nuclear (green) and cytoplasmic (pale green) TDP-43-derived fluorescence upon transfection. All data are percentages relative to
nuclear fluorescence after transfection with vehicle. The single (*), double (**), and triple (***) asterisks refer to p values lower than 0.05, 0.01, and 0.001,
respectively, relative to nuclear or cytoplasmic TDP-43-derived fluorescence of cells transfected with vehicle. C, representative confocal scanningmicroscope
images of NSC34 cells transfected with vehicle, 4 g/ml of control IBs and 5.7 g/ml of TDP-43 IBs and analyzed after transfection with anti-murine TDP-43
antibodies. The red fluorescence indicatesmurine endogenous TDP-43 detectedwith immunofluorescence.D, splicing analysis of themouse Sort1 gene upon
transfection of NSC34 cells with vehicle, 4g/ml of control IBs, and 5.7g/ml of TDP-43 IBs and corresponding densitometric analysis. Further details as in Fig.
4C. E, MTT reduction of NSC34 cells transfected with different concentrations of control IBs and TDP-43 IBs and analyzed after 24 h. The indicated IBs
concentrations refer to TDP-43 IBs, which exceed by 30% the corresponding values of control IBs (see the text for the explanation). F, representative confocal
microscope images of NSC34 cells showing caspase-3 activation, assessed using the fluorescent probe FAM-FLICA™ caspases 3 and 7, 24 h following trans-
fection with the indicated concentrations of control IBs and TDP-43 IBs. G, semi-quantitative analysis of the green fluorescence arising from caspase-3
activation. Experimental errors are S.E. The single (*), double (**), and triple (***) asterisks refer to p values lower than 0.05, 0.01, and 0.001, respectively, relative
to cells transfected with vehicle.
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tion were calculated as increase percentages relative to basal
levels (for example, values of 213% and 191% were found in Fig.
6, B and D, respectively, for 50% nuclear depletion or cytosolic
enrichment, implying increases of 113% and 91% relative to
basal levels, respectively).
This analysis enabled the quantification of the degree of cyto-
toxicity of NSC34 cells resulting from the loss of nuclear
TDP-43 (LOF) and from the gain of aggregated TDP-43 in the
cytoplasm (GOF) in similar quantities (Fig. 6, E and F). Using
MTT reduction as a probe of toxicity (Fig. 6, A and C) we
obtained similar values for each function, i.e. decreases ofMTT
reduction of 29.5  (1.9)% and 23.7 (1.6)% at 50% nuclear
depletion or cytoplasmic enrichment, respectively (Fig. 6E),
corresponding to 55.4 (3.5)% and 44.6 (3.0)% of the total
observed toxicity, summing up both LOF and GOF contribu-
tions. Using caspase-3 activation as a probe of toxicity (Fig. 6, B
and D) we again obtained similar values, i.e. increases of
caspase-3 activity of 113.8 (4.2)% and 91.9 (4.0)% at 50%
nuclear depletion or cytoplasmic enrichment, respectively (Fig.
6F), corresponding to 55.3 (2.0)% and 44.7 (2.0)% of the
total observed toxicity, summing up both LOF and GOF con-
tributions. These data allow us to conclude that the GOF and
LOF mechanisms contribute to 45% and 55%, respectively,
for theNSC34 cell system used here, using both readouts of cell
toxicity.
All the data presented in this work, and particularly the cor-
relations and analyses presented in Fig. 6, are based on the levels
of nuclear and cytoplasmic TDP-43 measured with confocal
microscopy and anti-TDP-43 antibodies. The TDP-43 levels
were also, however, quantified using a Western blot analysis of
the nuclear and cytoplasmic fractions for NSC34 cells trans-
fected with representative amounts of the pCI-neo plasmid,
siRNA or TDP-43 IBs and anti-TDP-43 antibodies. The
TDP-43 levelsmeasuredwith theWestern blot technique in the
nucleus and cytosol following the various treatments were
found to agree clearly with the corresponding values obtained
with confocal microscopy (supplemental Fig. S5).
Finally, all the experiments presented in this work were car-
ried out on NSC34 cells. To extend the analysis to a different
cell type we repeated some of key experiments with siRNA and
TDP-43 IBs onmurine neuroblastomaN2a cells (supplemental
Figs. S6 and S7).We found that both a loss of nuclear TDP-43 in
the absence of cytoplasmic accumulation (supplemental Fig.
S6) and accumulation of TDP-43 inclusions in the absence of
nuclear TDP-43 depletion (supplemental Fig. S7) lead to levels
of toxicity similar to those observed in NSC34 cells under cor-
responding conditions, confirming that both LOF and GOF
mechanisms were similarly important in this cell type.
Discussion
Taken together, the data reported in this manuscript show
clearly that both nuclear depletion of soluble and functional
TDP-43 and accumulation of the same protein in the form of
cytoplasmic inclusions contribute to the deleterious effects
associated with the typical TDP-43 pathology observed in neu-
rons and motor neurons of individuals suffering from ALS and
FTLD-U. Moreover, the relative contributions of these two
effects appear to be clearly similar, i.e.55% and 45%, respec-
tively, independently of the used cell line (either NSC34 or
N2a), of the readout of cell toxicity (either MTT reduction or
caspase-3 activity measurements), of themethod used to quan-
tify TDP-43 levels (either confocal microscopy coupled to im-
munofluorescence or Western blotting analysis). This conclu-
sion reconciles the two apparently opposing theories that have
been advanced to explain the origins of ALS and FTLD-U as
either LOF or GOF diseases, by showing that these fatal and
highly debilitating disorders can arise from a combination of
FIGURE 6. A and B, MTT reduction (A) and caspase-3 activation (B) versus
nuclear TDP-43 levels in NSC34 cells transfected with plasmid (1–4 g) and
analyzed after 48 h or with 25 nM siRNA and analyzed after 48–72 h. Data
points refer to vehicle (●), 1 g plasmid (f), 2 g plasmid (), 4 g plasmid
(E), siRNA 48 h (), siRNA 63 h (), and siRNA 72 h (Œ). The solid lines repre-
sent the lines of best fit obtained using a second-order polynomial function,
which are also numerically reported in the figures. C andD, MTT reduction (C)
and caspase-3 activation (D) versus cytoplasmic TDP-43 levels in NSC34 cells
transfected with control IBs (16 g/ml) and TDP-43 IBs (1.425–22.8 g/ml)
and analyzed after transfection or 8 g of plasmid and analyzed 48 h after
transfection. Data points refer to control IBs (●), 1.425 g/ml TDP-43 IBs (f),
2.85g/ml TDP-43 IBs (black), 5.7g/ml TDP-43 IBs (Œ), 11.4g/ml TDP-43
IBs (E), 22.8 g/ml TDP-43 (), vehicle (ƒ) and 8 g plasmid (grey). The
solid lines represent the straight lines of best fit, which are also numerically
reported in the figures. E and F, decrease of MTT reduction (E) and increase of
caspase-3 activation (F) relative to transfectionwith vehiclewhennuclear loss
(light bars) or cytosolic accumulation (dark bars) corresponds to 50% of
nuclear endogenous TDP-43, as determined with transfection with vehicle.
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the two contributions that are synergic, and together exacer-
bate the effects of each on the pathological states associated
with TDP-43.
This conclusion provides a rational explanation of the fact
that many mutations associated with familial ALS or FTLD-U
are located within genes whose protein products are associat-
ed with RNA maturation, such as ANG (35), SETX (36),
HNRNPA1 (37), TARDBP (38), and FUS (39), whilemany other
mutations involve proteins that aggregate into intracellular
inclusions, such as TARDBP (38), FUS (39), SOD1 (40), and
C9ORF72 (41), or are involved in the clearance of misfolded
proteins via the ubiquitin-proteasome system or autophagy,
such as UBQLN2 (42), VCP (43), CHMP2B (44), and OPTN
(45).
In summary, therefore, these data provide a unifying descrip-
tion of the pathology of ALS and FTLD-U. In addition, they
have profound implications for the design of therapeutic strat-
egies aimed at intervening in the complex cascade of molecular
events that constitute ALS and FTLD-U pathogenesis, suggest-
ing that, to be fully effective, such strategies will need to be
based on the avoidance of both nuclear clearance and cytoplas-
mic aggregation of TDP-43.
Experimental Procedures
Cell Cultures—Murine NSC34 and N2a cell lines were cul-
tured as described in supplementary methods.
Transient Transfection—Overexpression of TDP-43 was car-
ried out using the pCI-neo plasmid expressing human TDP-43
(kindly provided by E. Buratti, Italy) as previously reported (13).
NSC34 cells were plated in 6-well plates containing coverslips
at 150,000 cells/well density. 24 h after plating, the cells were
washed with PBS and transfected using Lipofectamine 3000
(Life Technologies), according to the manufacturer’s instruc-
tions, with different quantities of plasmid (1, 2, 4, 6, 8, 10, 15,
and 20 g), 7 l of Lipofectamine, 10 l of transferrin 5 mg/li-
ter, and 5 l of P3000 reagent in DMEM for 3 h in a 5% CO2
humidified atmosphere at 37 °C. The cells were also transfected
with vehicle (transfectionmixwithout plasmid). 3 h after trans-
fection the DMEM was replaced with fresh complete medium,
the cells were incubated for 48 h and then the confocal micros-
copy experiments were performed. In a set of experiments
NSC34 cells were transfected with 4 and 10 g of plasmid and
analyzed after different lengths of time (0, 24, 48, and 72 h) for
a time-course analysis.
Transient transfection of pCI-neo plasmid expressing
human TDP-43 was also performed on NSC34 cells plated in
96-well plates at 15,000 cells/well density with different quan-
tities of plasmid (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.5, and 2 g), 0.7 l of
Lipofectamine, 1l of transferrin 5mg/liter and 0.5l of P3000
reagent. 48 h after transfection, the MTT reduction assay was
carried out (see below).
RNA Interference—NSC34 cells were plated in 6-well plates
containing coverslips at 150,000 cells/well density. 24 h after
plating, the cells were washed with PBS and transfected using
ON-TARGETplus Mouse Tardbp siRNA SMARTpool (GE
Dharmacon, Lafayette, CO), according to the manufacturer’s
instructions, with 25 nM small-interfering RNA (siRNA), 7l of
Lipofectamine, 10 l of 5 mg/liter transferrin in DMEM for 3 h
in a 5% CO2 humidified atmosphere at 37 °C. The cells were
also transfected with vehicle (transfectionmix without siRNA),
and also with control siRNA, consisting of a pool of 4 non-
targeting siRNAs. 3 h after transfection the DMEM was
replaced with fresh complete medium, the cells were incubated
for different lengths of time (48, 63, and 72 h) for a time-course
analysis, prior to analysis with confocal microscopy.
RNA interference of TDP-43 was also performed on NSC34
cells plated in 96-well plates at 15,000 cells/well density with 25
nM siRNA, 0.7l of Lipofectamine, and 1l of 5mg/liter trans-
ferrin. After different lengths of time (48, 63, and 72 h), the
MTT reduction assay was carried out (see below).
RNA interference of TDP-43 was also performed on N2a
cells plated in 6-well plates containing coverslips at 30,000
cells/well density for confocal microscopy and in 96-well plates
at 5,000 cells/well density for the MTT reduction assay. The
cells were transfected with vehicle and 25 nM siRNA, and the
RNAi of TDP-43 was analyzed 72 h after cell transfection.
Purification and Cell Internalization of TDP-43 IBs—Human
TDP-43was overexpressed in E. coli and the resulting inclusion
bodies (TDP-43 IBs)were purified, as previously described (46).
NSC34 cells were plated in 6-well plates containing coverslips
at 150,000 cells/well density. 24 h after plating, the cells were
washed with PBS and transfected using the PULSin protein
delivery reagent (Polyplus-transfection, Illkirch, France),
according to the manufacturer’s instructions, with different
concentrations of control IBs (2, 4, 8, and 16 g/ml) and
TDP-43 IBs (1.425, 2.85, 5.7, 11.4, and 22.8g/ml), 100l of 20
mM Hepes Buffer and 4 l of PLUSin reagent in cell culture
medium without FBS (46). The cells were also transfected with
vehicle (transfectionmixwithout IBs). 2 h after transfection the
medium without FBS was replaced with fresh complete
medium and the confocal microscopy experiments were car-
ried out (see below).
Transfection of IBs was also performed on NSC34 cells
plated in 96-well plate at 15,000 cells/well density with different
concentrations of control IBs and TDP-43 IBs, 10 l of 20 mM
Hepes Buffer and 0.4 l of PLUSin reagent. 24 h after transfec-
tion, the MTT reduction assay was carried out (see below).
The transfection of IBs was also carried out in N2a cells
plated in 6-well plates containing coverslips at 30,000 cells/well
density for confocal microscopy and in 96-well plates at 5,000
cells/well density for the MTT reduction assay. The cells were
transfected with vehicle, 4 g/ml of control IBs and 5.7 g/ml
of TDP-43 IBs. IBs internalization was analyzed after cell trans-
fection, whereas the cell viability was assessed after 24 h, as
described above.
Confocal Microscopy Analysis of TDP-43 Levels—NSC34
cells were transfected with 1–20 g of plasmid, 25 nM siRNA,
1.425–22.8 g/ml of TDP-43 IBs, or 1–16 g/ml of control IBs
and incubated for different lengths of time, as described above.
After washing with PBS, the cells were fixed in 2% (w/v) buff-
ered paraformaldehyde for 10 min at room temperature
(20 °C) and permeabilized with a solution of PBS plus 0.5%
(v/v) Triton X-100 and 0.5% bovine serum albumin (BSA) for 5
min at room temperature ( 20 °C). Then, the cells were incu-
bated for 60min at 37 °C with 1:500 dilutedmousemonoclonal
anti-TDP-43 antibodies (Novus Biologicals, Ltd, Cambridge,
LOF and GOFMechanisms of TDP-43 Proteinopathies
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UK) in PBS plus 1% of FBS, and for 90 min with 1:1000 diluted
Alexa Fluor 488-conjugated anti-mouse secondary antibodies
in PBS plus 1% of FBS. In another experimental set, N2a cells
were transfected with 25 nM siRNA, 5.7 g/ml of TDP-43 IBs,
or 4 g/ml of control IBs and analyzed as described above.
The analysis was repeated using antibodies that recognize
only themurine protein. NSC34 andN2a cells were transfected
with 4 and 10 g of plasmid, 4 g/ml of control IBs and 5.7
g/ml of TDP-43 IBs, and analyzed as described above using
1:500 diluted rabbit polyclonal anti murine TDP-43 antibodies
(LSBio, Seattle, WA) and 1:1000 diluted Alexa Fluor 594-con-
jugated anti-rabbit secondary antibodies.
Cells were analyzed using a Leica TCS SP5 confocal scanning
microscope (Leica Microsystems, Mannheim, Germany),
equipped with an argon laser source and a Leica Plan Apo 63
oil immersion objective. A series of optical sections (1024 
1024 pixels) 1.0 m in thickness was taken through the cell
depth for each sample examined. The confocal microscope was
set at optimal acquisition conditions of pinhole diameter,
detector gain and laser power, and the settingsweremaintained
constant for each analysis. To quantify the signal intensity,
10–22 cells in three different experiments were analyzed
using ImageJ software (NIH, Bethesda, MD) and both cyto-
plasmic and nuclear fluorescence intensities were expressed as
percentages compared with nuclear fluorescence measured
after transfection with the vehicle (taken as 100%).
MTT Reduction Assay—The MTT reduction assay was per-
formed on NSC34 cells transfected with vehicle, 1–20 g of
plasmid for 48 h, 25 nM siRNA for different lengths of time (48,
63, and 72 h), 1–16 g/ml of control IBs and 1.425–22.8 g/ml
of TDP-43 IBs for 24 h, as previously reported (47). Cell viability
was expressed as the percentage reduction of MTT in treated
cells relative to the cells treated with vehicle (taken as 100%).
The MTT test was also assessed on N2a cells transfected with
25 nM siRNA (72 h), 4g/ml of control IBs (24 h) and 5.7g/ml
of TDP-43 IBs (24 h).
Measurement of Caspase-3 Activity—The levels of caspase-3
activity were analyzed on NSC34 and N2a cells treated as
described in the previous subsection by using FAMFLICATM
caspases 3&7 solution (caspase 3&7 FLICA kit FAM-DEVD-
FMK, Immunochemistry Technologies, LLC, Bloomington,
MN) as previously reported (48). To quantify the signal inten-
sity of caspases 3 and 7 solution, 10–22 cells in three different
experiments were analyzed using ImageJ software (NIH,
Bethesda,MD), and the fluorescence intensities were expressed
as percentages compared with cells transfected with vehicle
(taken as 100%).
Splicing Analysis—The functionality of nuclear TDP-43 was
analyzed by monitoring its regulation of the splicing activity of
the mRNA transcribed from the mouse sortilin 1 (Sort1) gene,
as previously described (34). The inclusion of the sortilin exon
cassette (termed Ex17b) is generated and translated into pro-
tein upon TDP-43 down-regulation. NSC34 cells were trans-
fected with vehicle, 25 nM control siRNA, and 25 nM siRNA for
72 h, or with 4 g/ml control IBs and 5.7 g/ml TDP-43 IBs.
After treatment, RNAwas collected by using TRI Reagent (Sig-
ma-Aldrich). cDNA was prepared and subjected to PCR using
primers in exons 17 and 19 ofmouse Sort1. The relative levels of
exon inclusion were visualized on 1.5% agarose gels. A 350-bp
and a 250-bp band products were produced. The densitometric
analysis was carried out from three different experiments using
ImageJ software (NIH, Bethesda, MD).
Statistical Analysis—Data were expressed as means  S.E.
Comparisons between different groups were performed using
ANOVA followed by Bonferroni’s post-comparison test. A p
value lower than 0.05 was considered statistically significant.
The single (*), double (**), and triple (***) asterisks refer to p
values lower than 0.05, 0.01, and 0.001, respectively.
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 1 
SUPPLEMENTARY METHODS 
 
 
Cell cultures 
NSC34 is a hybrid cell line that retains the ability to proliferate and express several motor neuron 
characteristics (49) and were kindly provided by Neil Cashman. NSC34 was routinely maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM) with 5% fetal bovine serum (FBS), 1 mM 
glutamine, 1% sodium pyruvate and 1% antibiotics, as described previously (50). Murine Neuro2a 
(N2a) neuroblastoma cells (A.T.C.C., Manassas, VA, USA) were cultured in minimum essential 
medium eagle (MEM) supplemented with 10% FBS, 1 mM glutamine and 1% antibiotics, as 
described previously (51). Cell cultures were maintained in a 5% CO2 humidified atmosphere at 37 
°C and grown until they reached 80% confluence for a maximum of 20 passages. 
 
Analysis of phosphorylation and ubiquitination of TDP-43 IBs 
The analysis of phosphorylation and ubiquitination of TDP-43 was assessed on NSC34 cells plated 
in 6-well plates (150,000 cells/well density). After 48 h of transient transfection with vehicle, 10 µg 
of plasmid, 4 µg/mL of control IBs and 5.7 µg/mL of TDP-43 IBs, the incubation medium (DMEM) 
was replaced with fresh complete medium and the analysis was performed. After washing with 
PBS, cells were fixed in 2% (w/v) buffered paraformaldehyde for 10 min at room temperature (20 
°C) and permeabilized with a 0.5% (v/v) Triton X-100 solution for 5 min. The colocalization of 
TDP-43 or phosphorylated TDP-43 with ubiquitin was monitored using 1:350 rabbit polyclonal 
anti-TDP-43 antibody (Sigma-Aldrich, St. Louis, MO, USA) or 1:500 rabbit anti-TDP-43 
phosphorylation sites 409/410 (Cosmo Bio Co., Ltd., Tokyo, Japan) for 60 min at 37 °C, 1:150 
mouse monoclonal anti-ubiquitin antibodies (Life Technologies, CA, USA) for 60 min at 37 °C, 
and then with 1:1000 Alexa Fluor 488-conjugated secondary antibodies (Life Technologies, CA, 
USA) for 60 min at 37 °C and 594-conjugated secondary antibodies (Life Technologies, CA, USA) 
for 60 min at 37 °C. The colocalization of TDP-43 with ubiquitin was estimated for the regions of 
 2 
interest (12-22 cells) in three different experiments using the ImageJ (NIH, Bethesda, MD, USA) 
and JACOP plugin (rsb.info.nih.gov) software (52). 
 
Dot-Blot analysis 
To exclude a potential cross-reactivity of the anti-murine TDP-43 antibodies with TDP-43 IBs 
containing human TDP-43, we carried out a dot-blot analysis. Briefly, 2.0 µl of 1.0 µg/µl of control 
IBs and TDP-43 IBs were spotted onto PVDF membrane, and then incubated with 1:1000 dilution 
of mouse monoclonal anti-TDP-43 antibodies (Novus Biologicals, Ltd, Cambridge, UK) or 1:1000 
rabbit polyclonal anti-murine TDP-43 antibodies (LSBio, Seattle, WA), and then with 1:5000 
diluted peroxidase-conjugated anti-mouse secondary antibodies (Santa Cruz Biotechnology Inc.) or 
with 1:5000 diluted peroxidase-conjugated anti-rabbit secondary antibodies (Santa Cruz 
Biotechnology Inc.), respectively. 
 
Subcellular fractionation 
NSC34 cells plated in 6-well plates at 360,000 cells/well density were treated with vehicle, 4 and 10 
µg plasmid for 48 h, 25 nM siRNA for 72 h, 4 µg/mL of control IBs and 5.7 µg/mL TDP-43 IBs. 
After treatment, the cells were washed, centrifuged and collected with 250 µL cytosolic buffer 
consisting of 0.1% sodium citrate (w/v), 0.1 % Triton X-100, 1 mM PMSF and 1:1000 protease 
inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA). Following 1 h incubation at 4 °C the 
samples were subjected to three freeze-thaw cycles and centrifuged at 750 g for 10 min. The 
supernatant (cytoplasmic fraction) was collected and the pellet (nuclear fraction) was resuspended 
in the nuclear buffer (20 mM Hepes, 250 mM sucrose, 2 mM EGTA and 1 mM EDTA, pH 7.4), 
sonicated twice for 5 s on ice and then collected. Nuclear (N) and cytoplasmic (C) fractions were 
quantified using the Bradford Protein Assay (Bio-Rad, Hercules, CA, USA) and the distribution of 
TDP-43 was visualized by Western Blotting. 
 3 
In a further set of experiments, the cytoplasmic fractions of cells treated with 4 µg/mL of 
control IBs and 5.7 µg/mL of TDP-43 IBs were centrifuged at 22,000 g for 30 min and the pellet 
(P) and supernatant (SN) fractions were collected and analysed by Western Blotting. 
 
Western Blotting 
Immunoblot analysis of TDP-43 levels in nuclear and cytoplasmic fractions of NSC34 cell lysates 
were carried out on a 12% (w/v) SDS/PAGE, blotted onto a polyvinylidene difluoride (PVDF) 
Immobilio-P Transfer Membrane (Millipore Corporation, Bedford, MA, USA), incubated with 
1:1000 diluted mouse monoclonal anti-TDP-43 antibodies (Novus Biologicals, Ltd, Littleton, CO, 
USA) and with 1:5000 diluted peroxidase-conjugated anti-mouse secondary antibodies (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) or with 1:1000 diluted rabbit polyclonal anti GAPDH 
antibodies (Santa Cruz Biotechnology Inc.) and with 1:5000 diluted peroxidase-conjugated anti-
rabbit secondary antibodies (Santa Cruz Biotechnology Inc.) or with 1:500 goat polyclonal 
antibodies anti Ac-Histone H3 (Lys 9/14) and with 1:5000 diluted peroxidase-conjugated anti-goat 
secondary antibodies (Santa Cruz Biotechnology Inc.). Immunoblot analysis was also performed in 
cytoplasmic fractions of NSC34 cell lysates with 1:500 rabbit anti-TDP-43 phosphorylation sites 
409/410 antibodies (Cosmo Bio Co., Ltd., Tokyo, Japan) or 1:1000 diluted rabbit polyclonal anti 
GAPDH antibodies (Santa Cruz Biotechnology Inc.) and with 1:5000 diluted peroxidase-conjugated 
anti-rabbit secondary antibodies (Santa Cruz Biotechnology Inc.). The immunolabelled bands were 
detected using a Super Signal West Dura (Thermo Fisher Scientific, Waltham, MA, USA). The 
densitometric analysis was carried out using ImageJ software (NIH, Bethesda, MD, USA).  
 
SDS-PAGE of TDP-43 IBs 
Human TDP-43 was overexpressed in E. coli. The resulting cells were collected and lysed as 
previously described (46). The resulting inclusion bodies (TDP-43 IBs) were purified as previously 
described (46). The expression of human TDP-43 in E. coli and its presence in the supernatant (SN) 
 4 
or in the pellet (P) fractions after cell lysis and purification of IBs were checked by SDS-PAGE, 
using 12% (w/v) polyacrylamide gels. P and SN aliquots were collected and mixed with 4× sample 
buffer with 20% 2-mercaptoethanol. SDS-PAGE analysis was performed in accordance with 
Laemmli (53) using a 12% polyacrylamide gels. Proteins were visualized by Coomassie Blue 
staining (0.1% Coomassie Blue, 10% acetic acid, 40% methanol).  
 
 
 5 
SUPPLEMENTARY FIGURES AND LEGENDS 
 
 
 
 
 
Figure S1. (A) Representative confocal scanning microscope images showing the colocalization of 
cytoplasmic TDP-43 with ubiquitin-positive aggregates in NSC34 cells transfected with vehicle or 
10 µg of pCI-neo plasmid expressing human TDP-43. The green fluorescence indicates TDP-43 
detected with antibodies that recognize both the endogenous (murine) and exogenous (human) 
protein. The red fluorescence indicates ubiquitin. (B) Representative confocal scanning microscope 
images showing the colocalization of TDP-43 phosphorylated at Ser409/410 and ubiquitin-positive 
aggregates in NSC34 cells transfected with vehicle or 10 µg of pCI-neo plasmid expressing human 
TDP-43. Green and red fluorescence indicate TDP-43 phosphorylated at Ser409/410 and ubiquitin, 
respectively. The cytofluorograms at the right of each row of images show the cytoplasmic green 
fluorescence intensity (as pixel intensity, y axis) versus cytoplasmic red fluorescence intensity (x 
axis). The histograms show the percentage of colocalization on regions of interest (12–13 cells) 
using the ImageJ (NIH, Bethesda, MD, USA) and JACOP plugin (rsb.info.nih.gov) software. Error 
bars are SEM. The triple (***) asterisk refers to p values lower than 0.001 relative to cells 
transfected with vehicle. 
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Figure S2. Dot-blot analysis of bacterial control IBs devoid of TDP-43 (left) and bacterial IBs 
containing human TDP-43 (right) with mouse monoclonal anti-TDP-43 antibodies that recognise 
both murine and human TDP-43 (upper panel) and rabbit polyclonal anti- murine TDP-43 
antibodies that recognise only murine TDP-43 (bottom panel). The specificity of the antibodies 
raised against murine TDP-43 is shown by the lack of cross-reactivity to TDP-43 IBs containing 
human TDP-43 (bottom panel).  
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Figure S3. (A,B) SDS-PAGE analysis of proteins from E. coli cells containing control IBs (left) and 
TDP-43 IBs (right) after induction of the GST/TDP-43 fused protein with 1 mM IPTG for 16 h at 
37 °C. The lanes refer to total proteins after IPTG induction (lane 1), supernatant (SN) and pellet 
(P) fractions after cell lysis (lanes 2 and 3, respectively), and of SN and P after IB purification 
(lanes 4 and 5, respectively). The bands at 69 kDa indicate the fused GST/TDP-43 protein, that is 
absent in the control IBs samples. (C) Western blot analysis of the fused GST/TDP-43 distribution 
(69 kDa) in the P and SN of the cytoplasmic fraction in NSC34 cells transfected with vehicle, 4 
µg/mL control IBs and 5.7 µg/mL TDP-43 IBs. The detection of GAPDH (35 kDa) was carried out 
as a loading control (10 µg total protein). 
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Figure S4. (A) Representative confocal scanning microscope images showing the colocalization of 
cytoplasmic TDP-43 with ubiquitin-positive aggregates in NSC34 cells transfected with vehicle, 4 
µg/mL of control IBs or 5.7 µg/mL of TDP-43 IBs. Green and red fluorescence have the same 
meaning as in supplemental Fig. S1A. (B) Representative confocal scanning microscope images 
showing the colocalization of TDP-43 phosphorylated at Ser409/410 and ubiquitin-positive 
aggregates in NSC34 cells transfected with vehicle, 4 µg/mL control IBs or 5.7 µg/mL TDP-43 IBs. 
Green and red fluorescence have the same meaning as in supplemental Fig. S1B. The 
cytofluorograms and histograms have the same meaning as in supplemental Fig. S1. (C) Western 
blot analysis of the phosphorylated TDP-43 (pS409/410) levels in the cytoplasm of NSC34 cells 
transfected with vehicle, 4 µg/mL of control IBs and 5.7 µg/mL of TDP-43 IBs. The band at 71 kDa 
arises from the exogenous TDP-43 phosphorylated at Ser409/410 fused to GST. Detection of 
GAPDH (35 kDa) was carried out as a loading control for cytoplasmic fractions (30 µg total 
protein). 
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Figure S5. (A) Western blot analysis of the TDP-43 levels in the nucleus (N) and cytoplasm (C), in 
NSC34 cells transfected with vehicle, 4 and 10 µg of plasmid for 48 h, 25 nM siRNA for 72 h or 
with 4 µg/mL of control IBs and 5.7 µg/mL of TDP-43 IBs. TDP-43 is revealed as a band at 43 
kDa. In the latter sample the band at 69 kDa arises from the exogenous TDP-43 fused to GST. 
Detection of GAPDH (35 kDa) and Ac-Histone H3 (17 kDa) was carried out as a loading control 
for cytoplasmic and nuclear fractions, respectively (30 µg total protein). (B) Semi-quantitative 
analysis of nuclear (dark gray), cytoplasmic (pale gray) and total (blank) TDP-43 levels as 
percentages relative to nuclear levels after transfection with vehicle, obtained both from Western 
blotting (left graphs) and confocal microscopy (right graphs). Experimental errors are SEM. The 
single (*), double (**) and triple (***) asterisks refer to p values lower than 0.05, 0.01 and 0.001, 
respectively, relative to nuclear or cytoplasmic TDP-43 levels of cells transfected with vehicle. 
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Figure S6. (A) Representative confocal scanning microscope images of N2a cells transfected with 
vehicle and 25 nM siRNA and analysed 72 h after transfection. The green fluorescence indicates 
TDP-43 detected with immunofluorescence. (B) Semi-quantitative analysis of nuclear (green) and 
cytoplasmic (pale green) TDP-43-derived fluorescence upon transfection with vehicle and siRNA. 
The triple (***) asterisk refers to p values lower than 0.001, relative to nuclear TDP-43 derived 
fluorescence of cells transfected with vehicle. (C) MTT reduction of N2a cells transfected with 
siRNA and analysed 72 h after transfection. (D) Representative confocal microscope images 
showing caspase-3 activation in N2a cells, assessed using the fluorescent probe FAM-FLICA™ 
caspases 3 & 7. The images were acquired at 72h, following transfection with vehicle or 25 nM 
siRNA. (E) Semi-quantitative analysis of the green fluorescence arising from caspase-3 activation. 
Experimental errors are SEM. The triple (***) asterisk refers to p values lower than 0.001, relative 
to cells transfected with vehicle. 
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Figure S7. (A) Representative confocal scanning microscope images of N2a cells transfected with 
vehicle, 4 µg/mL of control IBs and 5.7 µg/mL of TDP-43 IBs and analysed after transfection. The 
green fluorescence indicates total TDP-43 (human and murine). (B) Semi-quantitative analysis of 
nuclear (green) and cytoplasmic (pale green) TDP-43-derived fluorescence upon transfection. All 
data are percentages relative to nuclear fluorescence after transfection with vehicle. The triple (***) 
asterisk refers to p values lower than 0.001, relative to nuclear or cytoplasmic TDP-43 of cells 
transfected with vehicle. (C) Confocal scanning microscope images of N2a cells transfected with 
vehicle, 4 µg/mL of control IBs and 5.7 µg/mL of TDP-43 IBs and analysed after transfection with 
anti-murine TDP-43 antibodies. The red fluorescence indicates murine endogenous TDP-43. (D) 
MTT reduction of N2a cells transfected with 4 µg/mL of control IBs and 5.7 µg/mL of TDP-43 IBs 
and analysed after 24 h. The indicated IBs concentrations refer to TDP-43 IBs, which exceed by 
30% the corresponding values of control IBs (see the text for the explanation). (E) Confocal 
microscope images of N2a cells showing caspase-3 activation, assessed using the fluorescent probe 
FAM-FLICA™ caspases 3 & 7, 24 h following transfection. Other details as in panel D. (F) Semi-
quantitative analysis of the green fluorescence arising from caspase-3 activation. Experimental 
errors are SEM. The triple (***) asterisk refers to p values lower than 0.001, relative to cells 
transfected with vehicle. 
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